TNF-α
Tumor necrosis factor alpha (TNF-α), belongs to the superfamily of TNF/TNFR cytokine superfamily, is a type II transmembrane protein (mTNF) with an intracellular N terminus that is produced as 26 kDa membrane-bound cytokine comprised of 233 amino acids. TNF-α also exists as a soluble cytokine (sTNF), which is a non-covalently bound 17 kDa trimer (157 amino acids with a 76 amino acid presequence) resulted from the cleavage of mTNF by TNF-α converting enzyme (TACE). Two distinct and highly affinitive receptors of TNF-α have been identified, including TNFR55 (a 55 kDa receptor) and TNFR75 (a 75 kDa receptor), through which multiple activities of TNF-α are mediated. TNF-α has been found to be involved in maintenance and homeostasis of the immune system, inflammation and host defence as well as a variety of pathological processes.
-
A3547 Lenalidomide hydrochlorideSummary: TNF-α secretion inhibitor
-
A3652 Necrostatin 22 CitationSummary: In vitro necroptosis inhibitor
-
A4211 Lenalidomide (CC-5013)Target: angiogenesisSummary: Antineoplastic agent,inhibits angiogenesis
-
A4212 Pomalidomide (CC-4047)Summary: Immunomodulator,antumor/anti-angiogenic
-
A4213 Necrostatin-15 CitationTarget: RIP kinasesSummary: RIP1 inhibitor
-
A4216 ThalidomideTarget: Ubiquitin E3 LigasesSummary: Immunomodulatory agent,sedative drug,angiogenesis inhibitor
-
B1188 Lenalidomide hemihydrateSummary: TNF-α secretion inhibitor
-
A2604 CelastrolTarget: ProteasomeSummary: Antioxidant, anti-inflammatory and immunosuppressive agent
-
B6109 CPI-1189Summary: necrosis factor (TNF) alpha inhibitor
-
B6194 GSK481Summary: RIP1(Receptor Interacting Protein Kinase 1) inhibitor